Clínic Barcelona

A monoclonal antibody shows greater efficacy than conventional chemotherapy in patients with advanced melanoma

The prestigious New England Journal of Medicine (NEJM) publishes an article in its latest issue that demonstrates the efficacy of a monoclonal antibody (Nivolumab) in increasing overall survival and response to treatment in patients with metastatic melanoma compared with conventional treatment with chemotherapy (Dacarbazine). Dr. Ana Arance, Senior Specialist of the Medical Oncology Department at Hospital Clínic, is one of the authors of this study, the first to analyze the use of this drug in previously untreated patients with disseminated melanoma. This new article positions the Medical Oncology Department, headed by Dr. Aleix Prat, as an international referent in the study of melanoma.